---
title: ICH Stability Studies CROs in Asia-Pacific
path: /services/stability-studies/apac
companies_count: 8
---

# ICH Stability Studies CROs in Asia-Pacific

8 published CROs match ICH Stability Studies in Asia-Pacific.

Locations in this set include United States, China, India, Australia, Italy, and Netherlands.

Capabilities that show up most often in this set: Biologics (Monoclonal Antibodies), Biologics (Other), Small Molecule, Vaccine, and Antibody-Drug Conjugate (ADC).

## Matching companies

- [Aragen Life Sciences](/companies/aragen)
  - Global CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
- [BioAgilytix](/companies/bioagilytix)
  - Bioanalytical CRO specializing in pharmacokinetics, immunogenicity, biomarkers, and CMC analytics with 30+ years of experience and 1,100+ employees conducting 5M+ tests annually.
- [ChemPartner](/companies/chempartner)
  - Global preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
- [PI Health Sciences](/companies/pihealthsciences)
  - PI Health Sciences is an integrated CRDMO offering end-to-end drug discovery, development, and manufacturing services with R&D and manufacturing locations in Europe and India.
- [Pharmaron](/companies/pharmaron)
  - Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- [ProBio](/companies/probio)
  - ProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization.
- [Syngene International](/companies/syngeneintl)
  - Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- [WuXi AppTec](/companies/wuxiapptec)
  - Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.